Decibel Therapeutics, Inc. - DBTX STOCK NEWS

Decibel Therapeutics (DBTX) reported positive interim analysis results from its Phase 1b trial of DB-020, showing its potential to protect against hearing loss induced by cisplatin chemotherapy. The data indicated that 87% of patients treated with DB-020 were partially or completely protected from ototoxicity. The company also anticipates several milestones in its gene therapy pipeline, including submissions for DB-OTO and candidate selection for AAV.103. Financially, Decibel has $125.6 million in cash and expects to fund operations into 2024 despite increased R&D expenses.

Decibel Therapeutics (Nasdaq: DBTX) announced positive top-line results from an interim analysis of its Phase 1b trial for DB-020, a treatment aimed at preventing cisplatin-induced hearing loss. The data revealed that 87% of patients who faced ototoxicity in their placebo ear were protected in their DB-020-treated ear. The trial, involving 19 cisplatin-naïve patients, demonstrated that DB-020 was well tolerated with mild to moderate adverse effects. Additionally, it indicated significant preservation of hearing and speech intelligibility, marking a promising step forward in protecting patients undergoing cisplatin chemotherapy.

Decibel Therapeutics (Nasdaq: DBTX) announced participation in a fireside chat at the Jefferies Global Healthcare Conference on June 10, 2022, at 9:00 a.m. ET. The chat will feature Chief Development Officer John Lee and Chief Financial Officer Lis Leiderman. Investors can access the live webcast through the Decibel Therapeutics website, with an archived replay available for 90 days after the event. Decibel focuses on innovative treatments for hearing and balance disorders, leveraging advanced gene therapy technologies and a proprietary research platform.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company focused on hearing and balance solutions, announced that CEO Laurence Reid will participate in a fireside chat during the H.C. Wainwright Global Investment Conference. The chat will be available on-demand starting May 24, 2022, at 7:00 a.m. E.T. Interested viewers can access the webcast in the Investors section of the Decibel Therapeutics website. An archived version will be available for 90 days following the event.

Decibel Therapeutics (DBTX) reported its financial results for Q1 2022, highlighting cash reserves of $139.4 million. Significant milestones are expected in 2022, including IND submission for DB-OTO and results from the Phase 1b trial of DB-020 for cisplatin-induced hearing loss. Both programs are in collaboration with Regeneron Pharmaceuticals. Research and development expenses rose to $7.5 million, while general and administrative costs increased to $6.6 million. The company anticipates funding its projects through 2024, driven by ongoing clinical trials and preclinical studies.

Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the ASGCT 25th Annual Meeting from May 15-19, 2022. The company will present its lead gene therapy, DB-OTO, aimed at restoring hearing in individuals with an otoferlin gene mutation. Additionally, two poster presentations will cover the AAV.104 and AAV.103 programs, targeting patients with stereocilin gene mutations and GJB2 deficiencies, respectively. Key presentations will be made by Dr. Orion Keifer Jr. on May 19 at 10:45 am ET and poster sessions on May 16 at 5:30 pm ET.

Decibel Therapeutics (Nasdaq: DBTX) announced its participation in two virtual investor conferences in March 2022. CEO Laurence Reid will take part in a fireside chat at the H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30 and a panel discussion on hearing restoration via gene therapy. Additionally, he will join a panel at the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on March 29. Webcasts of these events will be accessible on Decibel's website for 90 days post-event.

Decibel Therapeutics (Nasdaq: DBTX) provided a corporate update and financial results for Q4 and the full year 2021. The company anticipates key milestones in 2022, including submitting an IND for DB-OTO and initiating a Phase 1/2 trial for pediatric patients with congenital hearing loss. The collaboration with Regeneron has been extended, with a $10 million fee expected. As of December 31, 2021, cash and equivalents totaled $162.3 million, a significant increase from $54.3 million in 2020. R&D expenses rose to $29.8 million for 2021, up from $25.3 million in 2020.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology firm focused on hearing and balance treatments, announced that CEO Laurence Reid, Ph.D., will speak at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET. Interested parties can access the live webcast via the Decibel website, with an archived replay available for 90 days post-event. The company aims to develop transformative therapies, including its lead program, DB-OTO, targeting congenital hearing loss.